

## 2021 eCQM Flow eCQM Identifier: CMS347v4

**NOTE:** This flow diagram represents an overview of population criteria requirements. **Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.**

## Statin Therapy for the Prevention and Treatment of Cardiovascular Disease


Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:

\*Adults aged  $\geq 21$  years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR

\*Adults aged  $\geq 21$  years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level  $\geq 190$  mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; OR


\*Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL

**This eCQM is a patient-based measure**




2021 eCQM Flow  
eCQM Identifier: CMS347v4


Statin Therapy for the Prevention and Treatment of  
Cardiovascular Disease




2021 eCQM Flow  
eCQM Identifier: CMS347v4




Statin Therapy for the Prevention and Treatment of  
Cardiovascular Disease



2021 eCQM Flow  
eCQM Identifier: CMS347v4




Statin Therapy for the Prevention and Treatment of  
Cardiovascular Disease




2021 eCQM Flow  
eCQM Identifier: CMS347v4

Statin Therapy for the Prevention and Treatment of  
Cardiovascular Disease








2021 eCQM Flow  
eCQM Identifier: CMS347v4

Statin Therapy for the Prevention and Treatment of  
Cardiovascular Disease



2021 eCQM Flow  
eCQM Identifier: CMS347v4

Statin Therapy for the Prevention and Treatment of  
Cardiovascular Disease

**Sample Calculation:**

**Performance Rate\* (Population 1, 2, and 3) =**

$$\frac{\text{Numerator 1 (a}^1 + \text{a}^2 + \text{a}^3 = 120 \text{ patients)}}{\text{Denominator (b}^1 + \text{b}^2 + \text{b}^3 = 300 \text{ patients) - Denominator Exclusions (x}^1 + \text{x}^2 + \text{x}^3 = 60 \text{ patients) - Denominator Exceptions (c}^1 + \text{c}^2 + \text{c}^3 = 60 \text{ patients)}} = \frac{120}{180} = 67 \%$$

\* This eCQM is intended to have one performance rate



**eCQM Identifier: CMS347v4****eCQM Title: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease**

**NOTE:** This flow diagram represents an overview of population criteria requirements. Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.

**Description:** Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:

\*Adults aged 21 years and older who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR

\*Adults aged 21 years and older who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level greater than or equal to 190 milligrams per deciliter or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; OR

\*Adults aged 40 to 75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 milligrams per deciliter

**This eCQM is a patient-based measure.**

**eCQM Flow Narrative****Initial Population 1**

Start by identifying the Initial Population 1, which includes patients 21 years of age and older with an eligible encounter during the measurement period.

**Denominator 1**

The Denominator 1 criteria further constrain the Initial Population 1 to patients who have current or prior history of clinical atherosclerotic cardiovascular disease (ASCVD) or ASCVD procedure. In the sample calculation provided at the end of the eCQM flow, Denominator 1 is equal to 100 patients.

**Denominator Exclusions 1**

The Denominator Exclusions 1 criteria identify a subset of the Denominator 1 population by excluding patients who are pregnant at any time during the measurement period, patients who are breastfeeding at any time during the measurement period, and patients who have an active diagnosis of rhabdomyolysis at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exclusions 1 are equal to 20 patients.

**Numerator 1**

The Numerator 1 criteria identify a subset of the Denominator 1 population (that did not meet the Denominator Exclusions 1 criteria) by including patients who were ordered statin therapy during the measurement period or who were actively taking statin therapy through the end of the measurement period. In the sample calculation provided at the end of the eCQM flow, Numerator 1 is equal to 40 patients.

**Denominator Exceptions 1**

The Denominator Exceptions 1 criteria identify patients from the Denominator 1 that did not meet the Denominator Exclusions 1 or Numerator 1 population criteria due to an adverse reaction, allergy, or intolerance to statins at any time during the measurement period; an order for or receiving palliative care or hospice care before the end of the measurement period; or an active diagnosis of hepatitis A,

hepatitis B, liver disease, or end-stage renal disease (ESRD) at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exceptions 1 are equal to 20 patients.

### **Initial Population 2**

Start by identifying the Initial Population 2, which includes patients 21 years of age and older with an eligible encounter during the measurement period.

### **Denominator 2**

The Denominator 2 criteria further constrain the Initial Population 2 to patients who have a current or prior LDL-C result of greater than or equal to 190 milligrams per deciliter without current or prior history of clinical ASCVD or ASCVD procedure OR a current or prior diagnosis of hypercholesterolemia (familial or pure) without current or prior history of clinical ASCVD or ASCVD procedure. In the sample calculation provided at the end of the eCQM flow, Denominator 2 is equal to 100 patients.

### **Denominator Exclusions 2**

The Denominator Exclusions 2 criteria identify a subset of the Denominator 2 population by excluding patients who are pregnant at any time during the measurement period, patients who are breastfeeding at any time during the measurement period, and patients who have an active diagnosis of rhabdomyolysis at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exclusions 2 are equal to 20 patients.

### **Numerator 2**

The Numerator 2 criteria identify a subset of the Denominator 2 population (that did not meet the Denominator Exclusions 2 criteria) by including patients who were ordered statin therapy during the measurement period or who were actively taking statin therapy through the end of the measurement period. In the sample calculation provided at the end of the eCQM flow, Numerator 2 is equal to 40 patients.

### **Denominator Exceptions 2**

The Denominator Exceptions 2 criteria identify patients from the Denominator 2 that did not meet the Denominator Exclusions 2 or Numerator 2 population criteria due to an adverse reaction, allergy, or intolerance to statins at any time during the measurement period; an order for or receiving palliative care or hospice care; or an active diagnosis of hepatitis A, hepatitis B, liver disease, or end-stage renal disease (ESRD) at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exceptions 2 are equal to 20 patients.

### **Initial Population 3**

Start by identifying the Initial Population 3, which includes patients 21 years of age and older with an eligible encounter during the measurement period.

### **Denominator 3**

The Denominator 3 criteria further constrain the Initial Population 3 to patients 40 to 75 years of age with an active diagnosis of type 1 or type 2 diabetes at any time during the measurement period who have an LDL-C result of 70 to 189 milligrams per deciliter two years before the start of or during the measurement period, without current or prior LDL-C result of greater than or equal to 190 milligrams per deciliter, without current or prior history of clinical ASCVD or ASCVD procedure, and without current or prior diagnosis of hypercholesterolemia (familial or pure). In the sample calculation provided at the end of the eCQM flow, Denominator 3 is equal to 100 patients.

**Denominator Exclusions 3**

The Denominator Exclusions 3 criteria identify a subset of the Denominator 3 population by excluding patients who are pregnant at any time during the measurement period, patients who are breastfeeding at any time during the measurement period, and patients who have an active diagnosis of rhabdomyolysis at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exclusions 3 are equal to 20 patients.

**Numerator 3**

The Numerator 3 criteria identify a subset of the Denominator 3 population (that did not meet the Denominator Exclusions 3 criteria) by including patients who were ordered statin therapy during the measurement period or who were actively taking statin therapy through the end of the measurement period. In the sample calculation provided at the end of the eCQM flow, Numerator 3 is equal to 40 patients.

**Denominator Exceptions 3**

The Denominator Exceptions 3 criteria identify patients from the Denominator 3 that did not meet the Denominator Exclusions 3 or Numerator 3 population criteria due to an adverse reaction, allergy, or intolerance to statins at any time during the measurement period; an order for or receiving palliative care or hospice care before the end of the measurement period; an active diagnosis of hepatitis A, hepatitis B, liver disease, or end-stage renal disease (ESRD) at any time during the measurement period; or most recent LDL-C within 3 years before the end of the measurement period with a result of less than 70 milligrams per deciliter. In the sample calculation provided at the end of the eCQM flow, the Denominator Exceptions 3 are equal to 20 patients.

**Sample Calculation**

A sample calculation is provided to help determine how the measure performance rate is derived. The measure performance rate is calculated by summing Numerator 1, Numerator 2, and Numerator 3 (total equals 120 patients) then dividing by the difference between of the sum of the Denominators (Denominator 1, Denominator 2, and Denominator 3) and the sum of the Denominator Exclusions (Denominator Exclusions 1, Denominator Exclusions 2, and Denominator Exclusions 3) and the sum of the Denominator Exceptions (Denominator Exceptions 1, Denominator Exceptions 2, and Denominator Exceptions 3) (total equals 180 patients), which is equal to a score of 67 percent.